business

Is Tyra Biosciences, Inc. (TYRA) Stock a Biotech Opportunity Ahead of Key SURF302 Trial Data?

Yahoo Finance · Jun 30, 2026, 1:07 PM · Also reported by 4 other sources

Read full story on Yahoo Finance → More top stories

Also covered by

Investing.com Mbx biosciences stock hits all-time high of 54.98 USD Investing.com Moleculin reports positive interim data from AML trial Investing.com Guggenheim reiterates Abivax stock rating on cancer data MarketWatch Alphabet’s stock slump is a ‘tactical buying opportunity,’ according to one analyst

Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop

Is Tyra Biosciences, Inc. (TYRA) Stock a Biotech Opportunity Ahead of Key SURF302 Trial Data?

Also covered by

More in business